Literature DB >> 198423

Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone.

R J Santen, S A Wells, S Runić, C Gupta, J Kendall, E B Rudy, E Samojlik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 198423     DOI： 10.1210/jcem-45-3-469

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  10 in total

Review 1.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

2.  Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.

Authors:  S A Wells; R J Santen; A Lipton; D E Haagensen; E J Ruby; H Harvey; W G Dilley
Journal:  Ann Surg       Date:  1978-05       Impact factor: 12.969

Review 3.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

4.  Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.

Authors:  B P Haynes; M Jarman; M Dowsett; A Mehta; P E Lønning; L J Griggs; A Jones; T Powles; R Stein; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.

Authors:  R J Santen
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

Review 6.  Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.

Authors:  E Samojlik; J D Veldhuis; S A Wells; R J Santen
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

7.  Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.

Authors:  P E Lønning; S Kvinnsland; T Thorsen; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

8.  Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer.

Authors:  P F Bruning; J G Bonfrèr; E Engelsman; E Hamersma-vd Linden; M de Jong-Bakker; W Nooyen
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

9.  Treatment Options in Cushing's Disease.

Authors:  Ahmed Rizk; Juergen Honegger; Monika Milian; Tsambika Psaras
Journal:  Clin Med Insights Oncol       Date:  2012-01-11

10.  Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism.

Authors:  P E Goss; M Jarman; L J Griggs
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.